Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.
You may also be interested in...
J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.
Ibrutinib Results Suggest Potential To Shake Up CLL Market
Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.
ASH Data Raise Hopes For Ibrutinib As Single Agent, Chemo-Free Option In CLL
With the latest response, safety and durability data creating a buzz at the American Society of Hematology, Pharmacyclics CMO Lori Anne Kunkel discusses possibility for accelerated approval in a high-risk type of chronic lymphocytic leukemia. Drug also shows promise in trials of a genetic subtype of diffuse large B-cell lymphoma and mantle cell lymphoma.